Marksans Pharma Ltd
MARKSANS
Company Profile
Business description
Marksans Pharma Ltd is a pharmaceutical company. The company is engaged in the research, manufacturing, and marketing of pharmaceutical formulations. It manufactures analgesics, gastroenterology, anti-diabetic, cardiovascular, pain management, gynecology, gastrointestinal, and oncologic drugs as well as antibiotics and antiallergic medications. Geographically, the majority of its revenue is generated from the United States and North America, followed by Europe and the UK, Australia and New Zealand, and the Rest of the World.
Contact
Veera Desai Extension Road
11th Floor, Grandeur
Opposite Gundecha Symphony
Oshiwara, Andheri (West)
MumbaiMH400053
INDT: +91 2240012000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 March 2027
Employees
2,235
Stocks News & Analysis
stocks
The 10 best US companies to invest in now
The stocks of these high-quality companies look cheap today.
stocks
Surge in combat drones drives upgrade for ASX share
Drone demand powers growth but investor optimism is overdone.
stocks
Meta: Meta launches enterprise offering to open up another way to monetize AI investments
The market’s negative reaction to the announcement signals that investors, much like us, are not super excited about Meta’s prospects in the enterprise market.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,846.60 | 52.20 | 0.59% |
| CAC 40 | 7,835.31 | 129.20 | -1.62% |
| DAX 40 | 24,939.35 | 259.84 | -1.03% |
| Dow JONES (US) | 50,926.56 | 20.51 | 0.04% |
| FTSE 100 | 10,428.27 | 177.73 | -1.68% |
| HKSE | 23,948.62 | 664.65 | -2.70% |
| NASDAQ | 26,871.60 | 10.53 | 0.04% |
| Nikkei 225 | 68,234.25 | 722.47 | -1.05% |
| NZX 50 Index | 13,680.49 | 130.02 | -0.94% |
| S&P 500 | 7,666.45 | 14.91 | 0.19% |
| S&P/ASX 200 | 8,673.30 | 58.90 | 0.68% |
| SSE Composite Index | 3,842.19 | 11.74 | 0.31% |